估算激素受体阳性乳腺癌女性长期死亡率:ESTIMATE工具
基于SEER登记库1990至2006年确诊的264,237例浸润性、非转移性、激素受体阳性乳腺癌女性,采用Gray子分布法开发交互式工具ESTIMATE,可按患者与肿瘤特征及诊断后任意时点,估算至诊断后20年的乳腺癌特异性死亡、非乳腺癌特异性死亡及全因死亡的残余累积风险。
要点
- ESTIMATE基于SEER登记库264,237例非转移性激素受体阳性乳腺癌女性数据开发。
- 工具可输入患者与肿瘤特征及期望时间范围,输出诊断后至20年的残余累积风险。
- 40-49岁、T1cN1、II级且已存活7年者,未来13年乳腺癌特异性死亡残余累积风险为14%(95%CI:11.9%-16.1%)。
核心结论
- ESTIMATE可提供激素受体阳性乳腺癌诊断后至20年的基于人群的乳腺癌特异性死亡、非乳腺癌特异性死亡及全因死亡风险,基于患者与肿瘤特征。
- ESTIMATE可为预后讨论、竞争风险之间的平衡提供信息,并辅助临床决策。
研究设计与样本
- 使用SEER登记库数据,纳入1990至2006年确诊的264,237例浸润性、非转移性、激素受体阳性乳腺癌女性。
- 采用Gray子分布法,按基线临床与病理变量定义患者亚组,开发提供诊断后任意指定时点至第20年乳腺癌特异性死亡与非乳腺癌特异性死亡残余累积风险的非参数估计工具。
主要发现
- ESTIMATE允许用户输入患者与肿瘤特征及期望的时间范围。
- 40-49岁、诊断为T1cN1、II级乳腺癌且已存活7年的患者,未来13年乳腺癌特异性死亡残余累积风险为14%(95%CI:11.9%-16.1%)。
- 上述同一组患者同期非乳腺癌特异性死亡残余累积风险为6.4%(95%CI:4.7%-8.1%)。
关键数值与推荐
- 40-49岁、T1cN1、II级、已存活7年者,未来13年乳腺癌特异性死亡残余累积风险14%(95%CI:11.9%-16.1%)。
- 同一组患者同期非乳腺癌特异性死亡残余累积风险6.4%(95%CI:4.7%-8.1%)。
临床怎么用
- ESTIMATE可辅助关于预后的讨论、竞争风险之间的平衡以及临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The risk of breast cancer-specific mortality (BCSM) persists for at least 20 years from diagnosis. Estimating the risk of BCSM over this extended period along with competing risks of death would aid clinical decision-making. We aimed to develop an interactive tool called 'ESTIMATE', to explore the Surveillance, Epidemiology, and End Results (SEER) registry to quantify residual risks of BCSM, non-BCSM and all-cause mortality in non-metastatic, hormone receptor (HR)-positive breast cancer patient subgroups at any given time after diagnosis, up to 20 years. METHODS: Using SEER data, we included 264,237 women with invasive, non-metastatic, HR-positive breast cancer diagnosed from 1990 to 2006. We developed a tool that provides a nonparametric estimate of the residual cumulative risk of BCSM and non-BCSM by year 20 after any specified time from initial diagnosis, among patients defined by baseline clinical and pathologic variables, using Gray's subdistribution method. RESULTS: ESTIMATE allows the user to input patient and tumour characteristics and the preferred timeframe. For example, patients in the age group of 40-49 diagnosed with T1cN1, grade II breast cancer who survived 7 years, have a 14% (95% confidence interval [CI]: 11.9%-16.1%) residual cumulative risk of BCSM in the next 13 years, and a 6.4% (95% CI: 4.7%-8.1%) residual cumulative risk of non-BCSM over the same period. CONCLUSIONS: ESTIMATE provides population-based risks of BCSM, non-BCSM and all-cause mortality through 20 years after diagnosis of HR-positive breast cancer, based on patient and tumour characteristics. ESTIMATE can inform discussions about prognosis, a balance between competing risks and aid clinical decision-making.
引用
- Leone JP, Graham N, Tolaney SM, et al. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. Eur J Cancer. 2022. PMID: 35841843. doi:10.1016/j.ejca.2022.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。